LENZ Therapeutics Statistics
Total Valuation
LENZ has a market cap or net worth of $826.65 million. The enterprise value is $633.86 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LENZ has 28.15 million shares outstanding. The number of shares has increased by 917.91% in one year.
| Current Share Class | 28.15M |
| Shares Outstanding | 28.15M |
| Shares Change (YoY) | +917.91% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | 41.69% |
| Float | 11.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 27.51 |
| PB Ratio | 4.21 |
| P/TBV Ratio | 4.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 23.09 |
| Quick Ratio | 22.64 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.47% and return on invested capital (ROIC) is -18.96%.
| Return on Equity (ROE) | -24.47% |
| Return on Assets (ROA) | -17.75% |
| Return on Invested Capital (ROIC) | -18.96% |
| Return on Capital Employed (ROCE) | -30.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LENZ has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +86.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +86.71% |
| 50-Day Moving Average | 24.76 |
| 200-Day Moving Average | 26.13 |
| Relative Strength Index (RSI) | 60.82 |
| Average Volume (20 Days) | 267,168 |
Short Selling Information
The latest short interest is 3.19 million, so 11.34% of the outstanding shares have been sold short.
| Short Interest | 3.19M |
| Short Previous Month | 2.89M |
| Short % of Shares Out | 11.34% |
| Short % of Float | 27.01% |
| Short Ratio (days to cover) | 10.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.45M |
| Pretax Income | -117.37M |
| Net Income | -47.74M |
| EBITDA | -59.36M |
| EBIT | -59.45M |
| Earnings Per Share (EPS) | -$1.77 |
Full Income StatementBalance Sheet
The company has $193.98 million in cash and $1.18 million in debt, giving a net cash position of $192.79 million or $6.85 per share.
| Cash & Cash Equivalents | 193.98M |
| Total Debt | 1.18M |
| Net Cash | 192.79M |
| Net Cash Per Share | $6.85 |
| Equity (Book Value) | 192.01M |
| Book Value Per Share | 6.97 |
| Working Capital | 189.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$51.50 million and capital expenditures -$578,000, giving a free cash flow of -$52.08 million.
| Operating Cash Flow | -51.50M |
| Capital Expenditures | -578,000 |
| Free Cash Flow | -52.08M |
| FCF Per Share | -$1.85 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |